Scoring big pharma’s match with superbugs - March, 2018
So-called superbugs, germs resistant to one or more of the medications meant to kill them, represent a new villain in the global fight for human health and welfare. Pharmaceutical companies are pivotal in combating this global health emergency. Last month the Access to Medicine Foundation announced a new way to track drug companies’ efforts in this fight. Consumers, policymakers, and other drug companies can consult the Antimicrobial Resistance Benchmark to find out what companies are doing (and which are doing the most) to ensure that antimicrobials remain a useful part of our medical arsenal. But how exactly does a drug company fight superbugs?
Read the rest of the story here | See the Evo in the News archive